Search 

Late stage specialty CNS pharmaceutical company with neurology and psych assets looking for partnerships for in and out license.

Teikoku Pharma USA Inc., a wholly-owned subsidiary of Teikoku Seiyaku Inc. of Japan, is an international specialty pharmaceutical company that develops, and manufactures pharmaceutical products. Teikoku focuses its efforts in three therapeutic areas; Pain Management, CNS and Oncology.  Teikoku's main product is Lidoderm® (Lidocaine 5% Patch) for PHN, distributed by Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe. Our core technology platforms include; passive and active transdermal delivery systems as well as injectables. We are currently actively seeking to in-license/acquire later stage product for the US, Europe and Japan.

TherapeuticsMD (TXMD) is a publicly traded Women’s Health company located in South Florida.

TXMD currently has a national sales force calling on OB-GYNs in the US and a strong pipeline of late stage HRT products. We are currently pursuing in-licensing opportunities within the Women’s Health space and considering out-licensing International partners for our 3 late stage HRT products.

Theravance, Inc. - Medicines that Make A Difference®

Summary Products / Services / Technologies

Collaborations and Clients

Upsher-Smith Laboratories, Inc. is pursuing improved drug therapies to improve people’s lives.  The evolution of their company is driven by the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations.  Their perspective is not “more products,” but the right products that make people’s lives better.  At every level of their business, they are driven to be the best.

Upsher-Smith is actively pursuing product development opportunities in the therapeutic areas of epilepsy and Parkinson’s disease; their current product portfolio is focused in the areas of women’s health, dermatology, and cardiology.   

With a track record of successful collaboration in licensing and acquiring innovative products, Upsher-Smith is a trusted partner to many leading pharmaceutical companies, offering expertise in:   

• Conducting clinical trials to support safety and efficacy
• Preparing and managing submissions for the FDA review process
• Commercialization and distribution of products to the retail and wholesale trade
• Marketing and sales promotions through sales force, national conventions, professional advertising, and other media 

As an independent and privately held company, Upsher-Smith acts swiftly to create the right partnerships and connections that build upon their success.

On August 14, 2012, the company completed its acquisition of UK-based Proximagen Group plc, a European biotechnology company focused on the development and commercialization of novel therapeutics for diseases of the central nervous system and inflammation. 

Upsher-Smith also has offices in Plymouth, MN, Denver, CO and Morristown, NJ.

“Advancing pharmacotherapy.  Improving lifeSM”….  As the company evolves, Upsher-Smith’s goal remains the same:  to assist individuals in making the best use of medicines.  This not only means producing quality pharmaceutical products, but providing access to them as well.  The company promises to provide reliable, affordable products that have a daily impact to improve lives.

Upsher-Smith’s vision is to become a leader in providing therapies that empower people suffering from central nervous system (CNS) diseases to lead healthy, productive lives.

We are a specialty pharmaceutical company intent on utilizing our proven business model of creating value through accretive product acquisitions or license agreements, sound marketing and distribution, and life cycle management.

In June 2012 we acquired Actimmune (Interferon Gamma) our first product acquisition.  Actimmune is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease and delaying time to disease progression in patients with Severe, Malignant Osteopetrosis.  

We are seeking to acquire both commercial and late stage specialty niche therapeutics.  

Vidara is a fully financed and profitable specialty pharmaceutical company.  

Zosano Pharma (ZP), a spin-off of J&J, offers a fully-developed and validated transdermal drug-delivery platform to deliver small molecules, peptides, proteins and vaccines on a band-aid like patch with the efficacy of injectables.

Totally pain-free, the ZP patch offers quick onset of action, delivers with the efficacy of an injection and is stable at room temperature. It has been successfully tested with 30 compounds. The most advanced product is PTH for severe osteoporosis with completed Ph2 studies. Rights to PTH for select Asian countries have been granted to Asahi-Kasei Pharma, Japan.

ZP products are produced in its own GMP manufacturing facility at a low cost and offer attractive margins versus currently-marketed injectables.

ZP products are attractive to patients (pain-free & don't require refrigeration), payors (priced competitively versus marketed products) and pharma companies (for life cycle extension with ZP IP extending to 2027).